Quantitative progesterone receptor expression and efficacy of anti-estrogen therapy in breast cancer

Shiuh-Wen Luoh, Betsy Ramsey, Byung Park, Edward Keenan

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The central role of estrogen receptor (ER) presence in predicting which breast cancer patients are likely to benefit from anti-estrogen therapies is well-established, but the added benefit of progesterone receptor (PR) and in particular low levels of PR is less well understood. The objective of this study was to determine the quantitative relationship between borderline levels of PR and subsequent benefit from anti-estrogen therapy. We examined data from 447 patients, age 50 or older. ER and PR levels were quantitated by conventional ligand binding assay and Scatchard plot analysis or by enzyme-linked immunoassay. Comparison of clinical outcome in relation with ER and PR status was calculated using Kaplan-Meier actuarial survival analysis and the log-rank test. Subpopulation treatment effect pattern plot (STEPP) analysis was used to explore the interaction between treatment effects and ER or PR levels for the 409 patients with ER values greater than 0. For anti-estrogen treated patients, when the ER and PR positivity cut-off was set at 1.0 fmole/mg protein, there was a statistically significant advantage for patients with ER+PR+ over ER+ PR- tumors for both breast cancer-free interval (BCFI) and overall survival (OS). STEPP analysis found no overall interaction between treatment outcome (5 year survival probability) and levels of hormone receptor. However, patients with borderline PR levels did not appear to benefit from anti-estrogen therapy. PR levels above borderline in addition to the presence of ER predicts an increased probability of benefit from anti-estrogen therapy in breast cancer patients.

Original languageEnglish (US)
Pages (from-to)46-52
Number of pages7
JournalBreast Journal
Volume20
Issue number1
DOIs
StatePublished - Jan 2014

Fingerprint

Progesterone Receptors
Estrogens
Estrogen Receptors
Breast Neoplasms
Therapeutics
Actuarial Analysis
Survival
Survival Analysis
Immunoenzyme Techniques
Hormones
Ligands

Keywords

  • anti-estrogen therapy
  • predictive marker
  • progesterone receptor

ASJC Scopus subject areas

  • Internal Medicine
  • Oncology
  • Surgery

Cite this

Quantitative progesterone receptor expression and efficacy of anti-estrogen therapy in breast cancer. / Luoh, Shiuh-Wen; Ramsey, Betsy; Park, Byung; Keenan, Edward.

In: Breast Journal, Vol. 20, No. 1, 01.2014, p. 46-52.

Research output: Contribution to journalArticle

@article{622abb6e2cb54b2fb461aba6995b6c69,
title = "Quantitative progesterone receptor expression and efficacy of anti-estrogen therapy in breast cancer",
abstract = "The central role of estrogen receptor (ER) presence in predicting which breast cancer patients are likely to benefit from anti-estrogen therapies is well-established, but the added benefit of progesterone receptor (PR) and in particular low levels of PR is less well understood. The objective of this study was to determine the quantitative relationship between borderline levels of PR and subsequent benefit from anti-estrogen therapy. We examined data from 447 patients, age 50 or older. ER and PR levels were quantitated by conventional ligand binding assay and Scatchard plot analysis or by enzyme-linked immunoassay. Comparison of clinical outcome in relation with ER and PR status was calculated using Kaplan-Meier actuarial survival analysis and the log-rank test. Subpopulation treatment effect pattern plot (STEPP) analysis was used to explore the interaction between treatment effects and ER or PR levels for the 409 patients with ER values greater than 0. For anti-estrogen treated patients, when the ER and PR positivity cut-off was set at 1.0 fmole/mg protein, there was a statistically significant advantage for patients with ER+PR+ over ER+ PR- tumors for both breast cancer-free interval (BCFI) and overall survival (OS). STEPP analysis found no overall interaction between treatment outcome (5 year survival probability) and levels of hormone receptor. However, patients with borderline PR levels did not appear to benefit from anti-estrogen therapy. PR levels above borderline in addition to the presence of ER predicts an increased probability of benefit from anti-estrogen therapy in breast cancer patients.",
keywords = "anti-estrogen therapy, predictive marker, progesterone receptor",
author = "Shiuh-Wen Luoh and Betsy Ramsey and Byung Park and Edward Keenan",
year = "2014",
month = "1",
doi = "10.1111/tbj.12200",
language = "English (US)",
volume = "20",
pages = "46--52",
journal = "Breast Journal",
issn = "1075-122X",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Quantitative progesterone receptor expression and efficacy of anti-estrogen therapy in breast cancer

AU - Luoh, Shiuh-Wen

AU - Ramsey, Betsy

AU - Park, Byung

AU - Keenan, Edward

PY - 2014/1

Y1 - 2014/1

N2 - The central role of estrogen receptor (ER) presence in predicting which breast cancer patients are likely to benefit from anti-estrogen therapies is well-established, but the added benefit of progesterone receptor (PR) and in particular low levels of PR is less well understood. The objective of this study was to determine the quantitative relationship between borderline levels of PR and subsequent benefit from anti-estrogen therapy. We examined data from 447 patients, age 50 or older. ER and PR levels were quantitated by conventional ligand binding assay and Scatchard plot analysis or by enzyme-linked immunoassay. Comparison of clinical outcome in relation with ER and PR status was calculated using Kaplan-Meier actuarial survival analysis and the log-rank test. Subpopulation treatment effect pattern plot (STEPP) analysis was used to explore the interaction between treatment effects and ER or PR levels for the 409 patients with ER values greater than 0. For anti-estrogen treated patients, when the ER and PR positivity cut-off was set at 1.0 fmole/mg protein, there was a statistically significant advantage for patients with ER+PR+ over ER+ PR- tumors for both breast cancer-free interval (BCFI) and overall survival (OS). STEPP analysis found no overall interaction between treatment outcome (5 year survival probability) and levels of hormone receptor. However, patients with borderline PR levels did not appear to benefit from anti-estrogen therapy. PR levels above borderline in addition to the presence of ER predicts an increased probability of benefit from anti-estrogen therapy in breast cancer patients.

AB - The central role of estrogen receptor (ER) presence in predicting which breast cancer patients are likely to benefit from anti-estrogen therapies is well-established, but the added benefit of progesterone receptor (PR) and in particular low levels of PR is less well understood. The objective of this study was to determine the quantitative relationship between borderline levels of PR and subsequent benefit from anti-estrogen therapy. We examined data from 447 patients, age 50 or older. ER and PR levels were quantitated by conventional ligand binding assay and Scatchard plot analysis or by enzyme-linked immunoassay. Comparison of clinical outcome in relation with ER and PR status was calculated using Kaplan-Meier actuarial survival analysis and the log-rank test. Subpopulation treatment effect pattern plot (STEPP) analysis was used to explore the interaction between treatment effects and ER or PR levels for the 409 patients with ER values greater than 0. For anti-estrogen treated patients, when the ER and PR positivity cut-off was set at 1.0 fmole/mg protein, there was a statistically significant advantage for patients with ER+PR+ over ER+ PR- tumors for both breast cancer-free interval (BCFI) and overall survival (OS). STEPP analysis found no overall interaction between treatment outcome (5 year survival probability) and levels of hormone receptor. However, patients with borderline PR levels did not appear to benefit from anti-estrogen therapy. PR levels above borderline in addition to the presence of ER predicts an increased probability of benefit from anti-estrogen therapy in breast cancer patients.

KW - anti-estrogen therapy

KW - predictive marker

KW - progesterone receptor

UR - http://www.scopus.com/inward/record.url?scp=84892818926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892818926&partnerID=8YFLogxK

U2 - 10.1111/tbj.12200

DO - 10.1111/tbj.12200

M3 - Article

VL - 20

SP - 46

EP - 52

JO - Breast Journal

JF - Breast Journal

SN - 1075-122X

IS - 1

ER -